| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56ee5285e8e8edccb061046ff20da7a6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02 |
| filingDate |
1991-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1996-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8111b48b54c55010e8a0a219106293e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6481e60872735440c03175995f59b53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_107782b69f6fe438c1503abb6e33e841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e83cb1ad6e772d493dc7a7573cc4ac6 |
| publicationDate |
1996-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0480440-B1 |
| titleOfInvention |
Monoclonal antibody against melanoma |
| abstract |
The invention relates to a process for the preparation of human antibodies directed against melanoma, in which B lymphocytes are isolated without previous immunisation from a healthy person, the isolated B lymphocytes are immortalised, antibodies from the immortalised B lymphocytes are examined by immunohistochemical analysis for binding to primary melanoma and/or melanoma metastases, the B lymphocyte clones which have a positive reaction are selected and cultivated, and monoclonal antibodies are obtained therefrom. The antibodies prepared by the process according to the invention are also claimed. |
| priorityDate |
1990-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |